Companies Dominating the Peripheral Neuritis Treatment Market
- Eli Lilly and Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott
- Bristol Myers Squibb Company
- Novartis AG
- Pfizer Inc.
- GSK Group of Companies
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- RxFunction, Inc.
- Cipla Limited
Browse Key Market Insights with Data Illustration:
In the News
-
Abbot - launched Proclaim DRG Neurostimulation System, a DRG stimulation therapy. It will involve surgically placing a stimulator that will target the dorsal root ganglion and relieve lower limb pain caused by CRPS.
-
Eli Lilly and Company - is acquiring Disarm Therapeutics, a biotechnology company. Disarm Therapeutics has developed SARM1 inhibitors to deliver treatments for peripheral neuropathy and neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis.
